<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1787">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04715295</url>
  </required_header>
  <id_info>
    <org_study_id>CNO0032020</org_study_id>
    <nct_id>NCT04715295</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19</brief_title>
  <acronym>DOXYCOV</acronym>
  <official_title>Open-label, Randomized Trial of the Safety and Efficacy of Doxycycline and Rivaroxaban Therapy Versus National Standard Therapy in Ambulatory Patients With Mild Symptomatic COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yaounde Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yaounde Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory study to evaluate the efficacy of Doxycycline (200mg on D1 to D7) and&#xD;
      Rivaroxaban (15 mg daily on D1 to D7) versus the combination of Hydroxychloroquine (400 mg on&#xD;
      D1 to D7) and Azithromycin (500 mg on D1 and 250mg on D2 to D5) as per national standard to&#xD;
      treat ambulatory mild COVID-19 patients, with the aim to achieve early negativity of RT-PCR&#xD;
      of SARS-CoV-2 from nasopharyngeal swab, and early clinical improvement and prevention of&#xD;
      severe disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an exploratory study to evaluate the efficacy of Doxycycline (200mg on D1 to D7) and&#xD;
      Rivaroxaban (15 mg on D1 to D7) versus combination of hydroxychloroquine (400 mg on D1 to D7)&#xD;
      and azithromycin (500 mg on D1 and 250mg on D2 to D5) to treat ambulatory patients with mild&#xD;
      COVID-19.&#xD;
&#xD;
      We aim to demonstrate early improvement of a clinical core set of outcomes and prevention of&#xD;
      clinical worsening, and early negativity of SARS-CoV-2 reverse transcription-polymerase chain&#xD;
      reaction (RT-PCR) among ambulatory patients with mild COVID-19 by treating them with&#xD;
      Doxycycline and Rivaroxaban compared to patients who receive Hydroxychloroquine and&#xD;
      Azithromycin as per National standard therapy of COVid-19.&#xD;
&#xD;
      Ambulatory patients with mild symptoms and with confirmed diagnosis of COVID-19 will receive&#xD;
      the treatment.&#xD;
&#xD;
      The primary objective of the study is to evaluate the Safety and Efficacy of Doxycycline and&#xD;
      Rivaroxaban versus National standard therapy of mild COVid-19.&#xD;
&#xD;
      The primary endpoint is failure (i.e severe evolution) measured as PaO2 &lt; 92% within 10 days&#xD;
      after initiation of treatment.&#xD;
&#xD;
      The secondary objectives of the study are to evaluate&#xD;
&#xD;
        -  Safety of the different investigational therapies up to D10 days of follow-up per arm,&#xD;
&#xD;
        -  Hospitalisation due to Covid 19 infection rate per arm,&#xD;
&#xD;
        -  Time to hospitalisation due to Covid 19 infection,&#xD;
&#xD;
        -  Cure rate by treatment arm and Death rate,&#xD;
&#xD;
        -  Worsening as assessed by the need for additional concomitant medication,&#xD;
&#xD;
        -  Efficacy in sub-groups of patients (with pre-existing conditions/co-morbidities and by&#xD;
           age group).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2020</start_date>
  <completion_date type="Anticipated">September 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical</measure>
    <time_frame>Day 1 to 10</time_frame>
    <description>Change of Clinical stage of COVID-19</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Virological</measure>
    <time_frame>Day 1 to 10</time_frame>
    <description>Time to negativity of SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) on nasopharyngeal swab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom remission</measure>
    <time_frame>Day 1 to 10</time_frame>
    <description>Time to remission of symptoms in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation</measure>
    <time_frame>Day 1 to 10</time_frame>
    <description>Need for hospitalisation due to worsening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 1 to 10</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological variables</measure>
    <time_frame>Day 1 to Day 7 and Day 10</time_frame>
    <description>Change from baseline of WBC count</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Doxycyclin and Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Doxycyclin 200 mg daily for 7 days with or without Rivaroxaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>National Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxychloroquine 400 mg daily for 5 days in combination with Azithromycin 500 mg on day 1 and 250 mg daily from day 2 through day 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline Tablets</intervention_name>
    <description>Doxycycline 200 mg daily for 7 days</description>
    <arm_group_label>Doxycyclin and Rivaroxaban</arm_group_label>
    <other_name>Doxycycline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 15Mg Tab</intervention_name>
    <description>Rivaroxaban 15 mg tablets daily from day 1 to day 10</description>
    <arm_group_label>Doxycyclin and Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Hydroxychloroquine and Azithromycin</intervention_name>
    <description>Hydroxychloroquine 400mg daily from day 1 to day 5 in combination with Azithromycin 500mg on day 1 and 250 mg daily from day 2 to day 5</description>
    <arm_group_label>National Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COVID-19 infection confirmed by SARS-Cov2 - RT PCR - as per protocol&#xD;
&#xD;
          -  Able to start the treatment within 24 hours from time of diagnosis&#xD;
&#xD;
          -  Patient with mild symptoms as defined by WHO, with PaO2 &gt; 93%&#xD;
&#xD;
          -  Signed written consent of the patient&#xD;
&#xD;
          -  Accepts and has the ability to be reached by phone during the study duration, plus a&#xD;
             designated a contact person who can be contacted in case of emergency&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Blood pressure &lt; 90/60mm Hg&#xD;
&#xD;
          -  Respiratory rate ≥ 30/min&#xD;
&#xD;
          -  Known cardiac condition&#xD;
&#xD;
          -  Known G6PD deficiency&#xD;
&#xD;
          -  Patients with &lt; 45kg&#xD;
&#xD;
          -  eGFR &lt; 30 ml/min or ALT ≥ 3N or body temperature ≥ 38°C or any life-threatening&#xD;
             comorbidity&#xD;
&#xD;
          -  Any reason that makes it impossible to monitor the patient during the study period&#xD;
&#xD;
          -  Baseline ECG prior to randomization showing QTc &gt; 500 ms&#xD;
&#xD;
          -  Ongoing treatment other than symptomatic&#xD;
&#xD;
          -  history of retinopathy&#xD;
&#xD;
          -  Absolute contra-indication to treatment with hydroxychloroquine (known&#xD;
             hypersensitivity, concomitant treatment at risk of torsades de pointes)&#xD;
&#xD;
          -  Contraindication to any study medication including allergy&#xD;
&#xD;
          -  Ongoing treatment with high dose systemic chronic corticosteroid (&gt; 40 mg)&#xD;
&#xD;
          -  Patients treated by immunosuppressants treatment at the time of randomization&#xD;
&#xD;
          -  Known Pregnant women and breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene Sobngwi</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Yaounde 1</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eugene Sobngwi, MD, PhD</last_name>
    <phone>+237675088750</phone>
    <email>sobngwieugene@yahoo.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charles Kouanfack, MD, PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yaounde Central Hospital</name>
      <address>
        <city>Yaounde</city>
        <state>Centre</state>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Cameroon</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yaounde Central Hospital</investigator_affiliation>
    <investigator_full_name>Sobngwi Eugene</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Doxycycline</keyword>
  <keyword>Rivaroxaban</keyword>
  <keyword>Hydroxychloroquine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared upon request and approval by the National COVID19 Scientific Board</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>one year after completion</ipd_time_frame>
    <ipd_access_criteria>Data will be shared upon request and approval by the National COVID19 Scientific Board</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

